Table 2.
Characteristics of studies conducted in Africa
| Variable description | (N = 456) |
|---|---|
| Target size | |
| Mean (SD) | 6119 (36536) |
| Median (Q1, Q3) | 264 (100, 1000) |
| Source register | |
| ANZCTR | 4 (0.9%) |
| CTRI | 15 (3.3%) |
| ChiCTR | 2 (0.4%) |
| ClinicalTrials.gov | 326 (71.5%) |
| EU Clinical Trials Register | 22 (4.8%) |
| German Clinical Trials Register | 3 (0.7%) |
| ISRCTN | 18 (3.9%) |
| JPRN | 5 (1.1%) |
| PACTR | 53 (11.6%) |
| REPEC | 7 (1.5%) |
| TCTR | 1 (0.2%) |
| Recruitment status | |
| Authorized | 20 (4.4%) |
| Not recruiting | 214 (46.9%) |
| Recruiting | 222 (48.7%) |
| Study type | |
| Expanded access | 2 (0.4%) |
| Interventional study | 270 (59.2%) |
| Observational study | 184 (40.4%) |
| Study design | |
| Randomized | 237 (52.0%) |
| Non-randomized | 21 (4.6%) |
| Single group interventional study | 12 (2.6%) |
| Blank | 166 (36.4%) |
| Other | 20 (4.4%) |
| Phase | |
| N/A | 82 (28.0%) |
| Phase 0 | 1 (0.3%) |
| Phase 1 | 30 (10.2%) |
| Phase 1/phase 2 | 5 (1.7%) |
| Phase 2 | 40 (13.7%) |
| Phase 2/phase 3 | 27 (9.2%) |
| Phase 3 | 89 (30.4%) |
| Phase 4 | 19 (6.5%) |
| Retrospective flag | |
| No | 76 (16.7%) |
| Yes | 380 (83.3%) |
| Sponsor | |
| Other research/industry | 202 (44.3%) |
| University | 254 (55.7%) |